Comparative study of safety and efficacy profile of repaglinide and voglibose on targeting post prandial hyperglycemia in patients with newly diagnosed type II diabetes mellitus
Loading...
Date
2018-12
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Medip Academy
Abstract
Background: In India the number of people with diabetes is increasing day-by-day. Due to a sole “Asian Indian Phenotype,” Indians develop diabetes an era earlier and have an earlier onset of complications. Therefore, it is essential to evaluate more effective treatment strategies at an earlier stage of disease progression.Methods: The present study was prospective, open label, comparative, randomized, parallel group, single center study. Comparison of two post prandial active treatment groups over a period of 3 months. Sixty patients of either sex in the age group of 30-60years with newly diagnosed type II diabetes mellitus, with prandial blood glucose levels >180mg% and <250mg% at screening as per ADA. The effect of repaglinide and voglibose were observed on various parameters i.e. HbA1c, FBS, PBS, BMI.Results: In repaglinide group the mean change in HbA1c from baseline to 3 months was 8.05 to 7.04 (-1.01); on the other hand, in voglibose group from baseline to 3 months was 8.0 to 7.18 (-0.82). Whereas, FBS from 137.57 to 122.90 (-16.67) in repaglinide group; in voglibose group from 139.87 to 125.13 (-14.74). Repaglinide statistically highly significant than voglibose group in improving glycemic indices.Conclusions: Though repaglinide and voglibose were equally effective in improving glycemic indices yet repaglinide showed better results in improving HbA1c, FBG, PBS as compared with voglibose. Repaglinide had minimal side effects as compared to voglibose.
Description
Keywords
Repaglinide, Type II diabetes mellitus, Voglibose
Citation
Bobde Jyoti, Kadam Rajesh, Bhosle Deepak. Comparative study of safety and efficacy profile of repaglinide and voglibose on targeting post prandial hyperglycemia in patients with newly diagnosed type II diabetes mellitus. International Journal of Basic & Clinical Pharmacology. 2018 Dec; 7(12): 2325-2331